The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations

British Journal of Pharmacology

Volumn 174, Issue 11, 2017, Pages 1349-1365

  Petrosino, Stefania ^a,b   Di Marzo, Vincenzo ^a  

^a CNR   (Italy)

^b Epitech Group SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; LUTEOLIN; MEMBRANE RECEPTOR; ORPHAN GPR55 RECEPTOR; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PICEID; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ETHANOLAMINE DERIVATIVE; NEUROPROTECTIVE AGENT; PALMITIC ACID DERIVATIVE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NOCICEPTION; NONHUMAN; PARKINSON DISEASE; PARTICLE SIZE; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; TRAUMATIC BRAIN INJURY; ANIMAL; DIET THERAPY; DIETARY SUPPLEMENT; INFLAMMATION; MEDICINAL CHEMISTRY; PROCEDURES;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMISTRY, PHARMACEUTICAL; DIETARY SUPPLEMENTS; ETHANOLAMINES; HUMANS; INFLAMMATION; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PALMITIC ACIDS; PARTICLE SIZE;

EID: 84994812885     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13580     Document Type: Review

References (179)

1. Abramo F, Campora L, Albanese F, della Valle MF, Cristino L, Petrosino S et al. (2014). Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis. BMC Vet Res 10: 21.
2. Ahmad A, Genovese T, Impellizzeri D, Crupi R, Velardi E, Marino A et al. (2012a). Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats. Brain Res 1477: 45–58.13
3. Ahmad A, Crupi R, Impellizzeri D, Campolo M, Marino A, Esposito E et al. (2012b). Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice. Brain Behav Immun 26: 1310–1321.
4. Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The concise guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.
5. Alexander SPH, Catterall WA, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels. Br J Pharmacol 172: 5904–5941.
6. Alexander SP, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The concise guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. Br J Pharmacol 172: 5956–5978.
7. Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015d). The concise guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
8. Aloe L, Leon A, Levi-Montalcini R (1993). A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 39: 145–147.
9. Ambrosino P, Soldovieri MV, Russo C, Taglialatela M (2013). Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol 168: 1430–1444.
10. Ambrosino P, Soldovieri MV, De Maria M, Russo C, Taglialatela M (2014). Functional and biochemical interaction between PPARα receptors and TRPV1 channels: potential role in PPARα agonists-mediated analgesia. Pharmacol Res 87: 113–122.
11. Andresen SR, Bing J, Hansen RM, Biering-Sørensen F, Johannesen IL, Hagen EM et al. (2016). Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial. Pain 157: 2097–2103.
12. Artamonov M, Zhukov O, Shuba I, Storozhuk L, Khmel T, Klimashevsky V et al. (2005). Incorporation of labelled N-acylethanolamine (NAE) into rat brain regions in vivo and adaptive properties of saturated NAE under x-ray irradiation. Ukr Biokhim Zh (1999) 77: 51–62.
13. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A et al. (2001). Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15: 300–302.
14. Basu S, Dittel BN (2011). Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 51: 26–38.
15. Berdyshev EV, Schmid PC, Dong Z, Schmid HH (2000). Stress-induced generation of N-acylethanolamines in mouse epidermal JB6 P+ cells. Biochem J 2: 369–374.
16. Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HH (2004). Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 88: 1159–1167.
17. Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B (2013). Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol Disord Drug Targets 12: 34–44.
18. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V (1997). Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 272: 3315–3323.
19. Blancaflor EB, Kilaru A, Keereetaweep J, Khan BR, Faure L, Chapman KD (2014). N-Acylethanolamines: lipid metabolites with functions in plant growth and development. Plant J 79: 568–583.
20. Borrelli F, Romano B, Petrosino S, Pagano E, Capasso R, Coppola D et al. (2015). Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br J Pharmacol 172: 142–158.
21. Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, −beta, and -gamma in the adult rat. Endocrinology 137: 354–366.
22. Calignano A, La Rana G, Giuffrida A, Piomelli D (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277–281.
23. Calignano A, La Rana G, Piomelli D (2001). Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419: 191–198.
24. Caltagirone C, Cisari C, Schievano C, Di Paola R, Cordaro M, Bruschetta G et al. (2016). Co-ultramicronized palmitoylethanolamide/luteolin in the treatment of cerebral ischemia: from rodent to man. Transl Stroke Res 7: 54–69.
25. Campora L, Miragliotta V, Ricci E, Cristino L, Di Marzo V, Albanese F et al. (2012). Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. Am J Vet Res 73: 988–995.
26. Capasso R, Izzo AA, Fezza F, Pinto A, Capasso F, Mascolo N et al. (2001). Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol 134: 945–950.
27. Capasso R, Orlando P, Pagano E, Aveta T, Buono L, Borrelli F et al. (2014). Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels. Br J Pharmacol 171: 4026–4037.
28. Caraceni P, Viola A, Piscitelli F, Giannone F, Berzigotti A, Cescon M et al. (2010). Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int 30: 816–825.
29. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389: 816–824.
30. Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A (2010). Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells. Vet Immunol Immunopathol 133: 9–15.
31. Cerrato S, Brazis P, Della Valle MF, Miolo A, Petrosino S, Di Marzo V et al. (2012). Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. Vet J 191: 377–382.
32. Chen J, Matias I, Dinh T, Lu T, Venezia S, Nieves A et al. (2005). Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun 330: 1062–1067.
33. Clemente S (2012). Amyotrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: a case report. CNS Neurol Disord Drug Targets 11: 933–936.
34. Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M et al. (2011). Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol 158: 82–86.
35. Coburn AF, Graham CE, Haninger J (1954). The effect of egg yolk in diets on anaphylactic arthritis (passive Arthus phenomenon) in the guinea pig. J Exp Med 100: 425–435.
36. Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L (2014). Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat 2014: 854560.
37. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G (2002). Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 135: 181–187.
38. Cordaro M, Impellizzeri D, Paterniti I, Bruschetta G, Siracusa R, De Stefano D et al. (2016). Neuroprotective effects of co-UltraPEALut on secondary inflammatory process and autophagy involved in traumatic brain injury. J Neurotrauma 33: 132–146.
39. Cortright DN, Szallasi A (2004). Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem 271: 1814–1819.
40. Costa B, Conti S, Giagnoni G, Colleoni M (2002). Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol 137: 413–420.
41. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G (2008). The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 139: 541–550.
42. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83–87.
43. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V (2006). Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139: 1405–1415.
44. Crupi R, Impellizzeri D, Bruschetta G, Cordaro M, Paterniti I, Siracusa R et al. (2016). Co-ultramicronized palmitoylethanolamide/luteolin promotes neuronal regeneration after spinal cord injury. Front Pharmacol 7: 47.
45. D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E et al. (2007). Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther 322: 1137–1143.
46. D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E et al. (2009). Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur J Pharmacol 613: 54–59.
47. D'Agostino G, Russo R, Avagliano C, Cristiano C, Meli R, Calignano A (2012). Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropsychopharmacology 37: 1784–1792.
48. Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, Capasso R et al. (2005). Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 48: 1154–1163.
49. Daynes RA, Jones DC (2002). Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2: 748–759.
50. De Filippis D, D'Amico A, Cipriano M, Petrosino S, Orlando P, Di Marzo V et al. (2010). Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacol Res 61: 321–328.
51. De Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli MP, de Novellis V et al. (2011). Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain 7: 3.
52. de Novellis V, Luongo L, Guida F, Cristino L, Palazzo E, Russo R et al. (2012). Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. Eur J Pharmacol 676: 41–50.
53. De Petrocellis L, Davis JB, Di Marzo V (2001). Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 506: 253–256.
54. Demuth DG, Molleman A (2006). Cannabinoid signalling. Life Sci 78: 549–563.
55. Di Cesare Mannelli L, D'Agostino G, Pacini A, Russo R, Zanardelli M, Ghelardini C et al. (2013). Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm 2013: 328797.
56. Di Marzo V, De Petrocellis L, Sepe N, Buono A (1996). Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J 316: 977–984.
57. Di Marzo V, De Petrocellis L (2010). Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 17: 1430–1449.
58. Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M et al. (2001). Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 358: 249–255.
59. Domínguez CM, Martín AD, Ferrer FG, Puertas MI, Muro AL, González JM et al. (2012). N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica. Pain Manag 2: 119–124.
60. Donvito G, Bettoni I, Comelli F, Colombo A, Costa B (2015). Palmitoylethanolamide relieves pain and preserves pancreatic islet cells in a murine model of diabetes. CNS Neurol Disord Drug Targets 14: 452–462.
61. Edwards JG (2014). TRPV1 in the central nervous system: synaptic plasticity, function, and pharmacological implications. Prog Drug Res 68: 77–104.
62. Epps DE, Schmid PC, Natarajan V, Schmid HH (1979). N-Acylethanolamine accumulation in infarcted myocardium. Biochem Biophys Res Commun 90: 628–633.
63. Esposito E, Cuzzocrea S (2013). Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. CNS Neurol Disord Drug Targets 12: 55–61.
64. Esposito E, Impellizzeri D, Mazzon E, Paterniti I, Cuzzocrea S (2012). Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. PLoS One 7.e41880
65. Esposito G, Capoccia E, Turco F, Palumbo I, Lu J, Steardo A et al. (2014). Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation. Gut 63: 1300–1312.
66. Esposito E, Impellizzeri D, Bruschetta G, Cordaro M, Siracusa R, Gugliandolo E et al. (2016). A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation. Eur J Pharmacol 782: 107–118.
67. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 92: 3376–3380.
68. Farquhar-Smith WP, Rice AS (2001). Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology 94: 507–513.
69. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N (2003). Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 23: 7767–7775.
70. Gabrielsson L, Mattsson S, Fowler CJ (2016). Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol 82: 932–942.
71. Ganley OH, Graessle OE, Robinson HJ (1958). Anti-inflammatory activity on compounds obtained from egg yolk, peanut oil, and soybean lecithin. J Lab Clin Med 51: 709–714.
72. Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF (2012). Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med 13: 1121–1130.
73. Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P et al. (2008). Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther 326: 12–23.
74. Ghafouri N, Ghafouri B, Larsson B, Turkina MV, Karlsson L, Fowler CJ et al. (2011). High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. PLoS One 6.e27257
75. Ghafouri N, Ghafouri B, Larsson B, Stensson N, Fowler CJ, Gerdle B (2013). Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. Pain 154: 1649–1658.
76. Ghafouri N, Ghafouri B, Fowler CJ, Larsson B, Turkina MV, Karlsson L et al. (2014). Effects of two different specific neck exercise interventions on palmitoylethanolamide and stearoylethanolamide concentrations in the interstitium of the trapezius muscle in women with chronic neck shoulder pain. Pain Med 15: 1379–1389.
77. Giuffrida A, Piomelli D (1998). Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett 422: 373–376.
78. Giugliano E, Cagnazzo E, Soave I, Lo Monte G, Wenger JM, Marci R (2013). The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain. Eur J Obstet Gynecol Reprod Biol 168: 209–213.
79. Gómez del Pulgar T, Velasco G, Guzmán M (2000). The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347: 369–373.
80. Gouveia-Figueira S, Nording ML (2014). Development and validation of a sensitive UPLC-ESI-MS/MS method for the simultaneous quantification of 15 endocannabinoids and related compounds in milk and other biofluids. Anal Chem 86: 1186–1195.
81. Grillo SL, Keereetaweep J, Grillo MA, Chapman KD, Koulen P (2013). N-Palmitoylethanolamine depot injection increased its tissue levels and those of other acylethanolamide lipids. Drug Des Devel Ther 7: 747–752.
82. Guida F, Luongo L, Marmo F, Romano R, Iannotta M, Napolitano F et al. (2015). Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice. Mol Brain 8: 47.
83. Guindon J, Hohmann AG (2009). The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 8: 403–421.
84. Henstridge CM, Balenga NA, Schröder R, Kargl JK, Platzer W, Martini L et al. (2010). GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 160: 604–614.
85. Ho WS, Barrett DA, Randall MD (2008). ‘Entourage’ effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 155: 837–846.
86. Iannotti FA, Hill CL, Leo A, Alhusaini A, Soubrane C, Mazzarella E et al. (2014). Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci 5: 1131–1141.
87. Iannotti FA, Di Marzo V, Petrosino S (2016). Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog Lipid Res 62: 107–128.
88. Impellizzeri D, Esposito E, Di Paola R, Ahmad A, Campolo M, Peli A et al. (2013). Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice. Arthritis Res Ther 15: R192.
89. Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, Esposito E et al. (2014). Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation 11: 136.
90. Impellizzeri D, Ahmad A, Bruschetta G, Di Paola R, Crupi R, Paterniti I et al. (2015). The anti-inflammatory effects of palmitoylethanolamide (PEA) on endotoxin-induced uveitis in rats. Eur J Pharmacol 761: 28–35.
91. Indraccolo U, Barbieri F (2010). Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. Eur J Obstet Gynecol Reprod Biol 150: 76–79.
92. Issemann I, Green S (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645–650.
93. Iuvone T, Affaitati G, De Filippis D, Lopopolo M, Grassia G, Lapenna D et al. (2016). Ultramicronized palmitoylethanolamide reduces viscerovisceral hyperalgesia in a rat model of endometriosis plus ureteral calculosis: role of mast cells. Pain 157: 80–91.
94. Izzo AA (2004). Cannabinoids and intestinal motility: welcome to CB2 receptors. Br J Pharmacol 142: 1201–1202.
95. Jaggar S, Hasnie FS, Sellaturay S, Rice AS (1998). The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76: 189–199.
96. Jean-Gilles L, Feng S, Tench CR, Chapman V, Kendall DA, Barrett DA et al. (2009). Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 287: 212–215.
97. Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y et al. (2008). Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55: 85–93.
98. Julius D (2013). TRP channels and pain. Annu Rev Cell Dev Biol 29: 355–384.
99. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S et al. (2007). Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316: 1494–1497.
100. Katona I, Sperlágh B, Sík A, Käfalvi A, Vizi ES, Mackie K et al. (1999). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19: 4544–4558.
101. Kilaru A, Blancaflor EB, Venables BJ, Tripathy S, Mysore KS, Chapman KD (2007). The N-acylethanolamine-mediated regulatory pathway in plants. Chem Biodivers 4: 1933–1955.
102. Kondo S, Sugiura T, Kodaka T, Kudo N, Waku K, Tokumura A (1998). Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis. Arch Biochem Biophys 354: 303–310.
103. Kuehl FA, Jacob TA, Ganley OH, Ormond RE, Meisinger MAP (1957). The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. J Am Chem Soc 79: 5577–5578.
104. Lam PM, Marczylo TH, Konje JC (2010). Simultaneous measurement of three N-acylethanolamides in human bio-matrices using ultra performance liquid chromatography–tandem mass spectrometry. Anal Bioanal Chem 398: 2089–2097.
105. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105: 2699–2704.
106. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A (1996). Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 19: 514–520.
107. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A et al. (2005a). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15–19.
108. Lo Verme J, La Rana G, Russo R, Calignano A, Piomelli D (2005b). The search for the palmitoylethanolamide receptor. Life Sci 77: 1685–1698.
109. Lo Verme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G et al. (2006). Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 319: 1051–1061.
110. Loría F, Petrosino S, Mestre L, Spagnolo A, Correa F, Hernangómez M et al. (2008). Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci 28: 633–641.
111. Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F et al. (2013). Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol Disord Drug Targets 12: 45–54.
112. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561–564.
113. Mattace Raso G, Russo R, Calignano A, Meli R (2014). Palmitoylethanolamide in CNS health and disease. Pharmacol Res 86: 32–41.
114. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A (1996). N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 300: 227–236.
115. Merriam FV, Wang ZY, Hillard CJ, Stuhr KL, Bjorling DE (2011). Inhibition of fatty acid amide hydrolase suppresses referred hyperalgesia induced by bladder inflammation. BJU Int 108: 1145–1149.
116. Muccioli GG, Stella N (2008). Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology 54: 16–22.
117. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61–65.
118. Murillo-Rodriguez E, Désarnaud F, Prospéro-García O (2006). Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci 79: 30–37.
119. Naccarato M, Pizzuti D, Petrosino S, Simonetto M, Ferigo L, Grandi FC et al. (2010). Possible anandamide and palmitoylethanolamide involvement in human stroke. Lipids Health Dis 9: 47.
120. Nagy I, Friston D, Valente JS, Torres Perez JV, Andreou AP (2014). Pharmacology of the capsaicin receptor, transient receptor potential vanilloid type-1 ion channel. Prog Drug Res 68: 39–76.
121. Nestmann ER (2016). Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential. Food Sci Nutr. doi:10.1002/fsn3.392.
122. Noli C, Della Valle MF, Miolo A, Medori C, Schievano C (2015). Efficacy of ultra-micronized palmitoylethanolamide in canine atopic dermatitis: an open-label multi-centre study. Vet Dermatol 26: 432–440.
123. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004). Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279: 5298–5305.
124. Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G (2016). Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis. Pain Physician 19: 11–24.
125. Palma E, Reyes-Ruiz JM, Lopergolo D, Roseti C, Bertollini C, Ruffolo G et al. (2016). Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc Natl Acad Sci U S A 113: 3060–3065.
126. Paterniti I, Impellizzeri D, Crupi R, Morabito R, Campolo M, Esposito E et al. (2013a). Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. J Neuroinflammation 10: 20.
127. Paterniti I, Impellizzeri D, Di Paola R, Navarra M, Cuzzocrea S, Esposito E (2013b). A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury. J Neuroinflammation 10: 91.
128. Paterniti I, Cordaro M, Campolo M, Siracusa R, Cornelius C, Navarra M et al. (2014). Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation. CNS Neurol Disord Drug Targets 13: 1530–1541.
129. Paterniti I, Di Paola R, Campolo M, Siracusa R, Cordaro M, Bruschetta G et al. (2015). Palmitoylethanolamide treatment reduces retinal inflammation in streptozotocin-induced diabetic rats. Eur J Pharmacol 769: 313–323.
130. Pertwee RG (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74: 129–180.
131. Pertwee RG (2007). GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 152: 984–986.
132. Pessina F, Capasso R, Borrelli F, Aveta T, Buono L, Valacchi G et al. (2015). Protective effect of palmitoylethanolamide in a rat model of cystitis. J Urol 193: 1401–1408.
133. Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S et al. (2007). Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52: 415–422.
134. Petrosino S, Cristino L, Karsak M, Gaffal E, Ueda N, Tüting T et al. (2010a). Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy 65: 698–711.
135. Petrosino S, Iuvone T, Di Marzo V (2010b). N-palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities. Biochimie 92: 724–727.
136. Petrosino S, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L et al. (2016a). The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at transient receptor potential vanilloid type-1 channels. Br J Pharmacol 173: 1154–1162.
137. Petrosino S, Puigdemont A, Della Valle MF, Fusco M, Verde R, Allarà M et al. (2016b). Adelmidrol increases the endogenous concentrations of palmitoylethanolamide in canine keratinocytes and down-regulates an inflammatory reaction in an in vitro model of contact allergic dermatitis. Vet J 207: 85–91.
138. Rahimi A, Faizi M, Talebi F, Noorbakhsh F, Kahrizi F, Naderi N (2015). Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. Neuroscience 290: 279–287.
139. Rasenack N, Müller BW (2004). Micron-size drug particles: common and novel micronization techniques. Pharm Dev Technol 9: 1–13.
140. Re G, Barbero R, Miolo A, Di Marzo V (2007). Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 173: 21–30.
141. Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA et al. (2008). Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 10: R43.
142. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092–1101.
143. Sailler S, Schmitz K, Jäger E, Ferreiros N, Wicker S, Zschiebsch K et al. (2014). Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans. Oncoscience 1: 272–282.
144. Sánchez MG, Ruiz-Llorente L, Sánchez AM, Díaz-Laviada I (2003). Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal 15: 851–859.
145. Sanchez AM, Cioffi R, Viganò P, Candiani M, Verde R, Piscitelli F et al. (2016). Elevated systemic levels of endocannabinoids and related mediators across the menstrual cycle in women with endometriosis. Reprod Sci 23: 1071–1079.
146. Sarnelli G, D'Alessandro A, Iuvone T, Capoccia E, Gigli S, Pesce M et al. (2016). Palmitoylethanolamide modulates inflammation-associated vascular endothelial growth factor (VEGF) signaling via the Akt/mTOR pathway in a selective peroxisome proliferator-activated receptor alpha (PPAR-α)-dependent manner. PLoS One 11.e0156198
147. Schäbitz WR, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S et al. (2002). Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke 33: 2112–2114.
148. Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C (2014). Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat 2014: 849623.
149. Schomacher M, Müller HD, Sommer C, Schwab S, Schäbitz WR (2008). Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res 1240: 213–220.
150. Schreiber D, Harlfinger S, Nolden BM, Gerth CW, Jaehde U, Schömig E et al. (2007). Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Anal Biochem 361: 162–168.
151. Schuel H, Burkman LJ, Lippes J, Crickard K, Forester E, Piomelli D et al. (2002). N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids 121: 211–227.
152. Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr et al. (2011). Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide. J Cell Mol Med 15: 2664–2674.
153. Scuderi C, Valenza M, Stecca C, Esposito G, Carratù MR, Steardo L (2012). Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α. J Neuroinflammation 9: 49.
154. Scuderi C, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S et al. (2014). Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death Dis 5.e1419
155. Sharir H, Console-Bram L, Mundy C, Popoff SN, Kapur A, Abood ME (2012). The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. J Neuroimmune Pharmacol 7: 856–865.
156. Sheu MY, Fowler AJ, Kao J, Schmuth M, Schoonjans K, Auwerx J et al. (2002). Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol 118: 94–101.
157. Siracusa R, Paterniti I, Impellizzeri D, Cordaro M, Crupi R, Navarra M et al. (2015a). The association of palmitoylethanolamide with luteolin decreases neuroinflammation and stimulates autophagy in Parkinson's disease model. CNS Neurol Disord Drug Targets 14: 1350–1365.
158. Siracusa R, Paterniti I, Bruschetta G, Cordaro M, Impellizzeri D, Crupi R et al. (2015b). The association of palmitoylethanolamide with luteolin decreases autophagy in spinal cord injury. Mol Neurobiol 53: 3783–3792.
159. Skaper SD, Facci L, Barbierato M, Zusso M, Bruschetta G, Impellizzeri D et al. (2015). N-Palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution. Mol Neurobiol 52: 1034–1042.
160. Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S et al. (2009). Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A 106: 20966–20971.
161. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.
162. Spaziano G, Luongo L, Guida F, Petrosino S, Matteis M, Palazzo E et al. (2015). Exposure to allergen causes changes in NTS neural activities after intratracheal capsaicin application, in endocannabinoid levels and in the glia morphology of NTS. Biomed Res Int 2015: 980983.
163. Spence JK, Bhattachar SN, Wesley JA, Martin PJ, Babu SR (2005). Increased dissolution rate and bioavailability through comicronization with microcrystalline cellulose. Pharm Dev Technol 10: 451–460.
164. Starowicz K, Cristino L, Di Marzo V (2008). TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr Pharm Des 14: 42–54.
165. Starowicz K, Makuch W, Osikowicz M, Piscitelli F, Petrosino S, Di Marzo V et al. (2012). Spinal anandamide produces analgesia in neuropathic rats: possible CB(1)- and TRPV1-mediated mechanisms. Neuropharmacology 62: 1746–1755.
166. Stella N (2010). Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58: 1017–1030.
167. Stella N, Piomelli D (2001). Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol 425: 189–196.
168. Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T et al. (2000). Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275: 605–612.
169. Tsuboi K, Sun YX, Okamoto Y, Araki N, Tonai T, Ueda N (2005). Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 280: 11082–11092.
170. Turu G, Hunyady L (2010). Signal transduction of the CB1 cannabinoid receptor. J Mol Endocrinol 44: 75–85.
171. Ueda N, Yamanaka K, Yamamoto S (2001). Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 276: 35552–35557.
172. Vacondio F, Bassi M, Silva C, Castelli R, Carmi C, Scalvini L et al. (2015). Amino acid derivatives as palmitoylethanolamide prodrugs: synthesis, in vitro metabolism and in vivo plasma profile in rats. PLoS One 10.e0128699
173. Venables BJ, Waggoner CA, Chapman KD (2005). N-Acylethanolamines in seeds of selected legumes. Phytochemistry 66: 1913–1918.
174. Walter L, Franklin A, Witting A, Moller T, Stella N (2002). Astrocytes in culture produce anandamide and other acylethanolamides. J Biol Chem 277: 20869–20876.
175. Whiteside GT, Lee GP, Valenzano KJ (2007). The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 14: 917–936.
176. Yang H, Zhou J, Lehmann C (2016). GPR55 - a putative "type 3" cannabinoid receptor in inflammation. J Basic Clin Physiol Pharmacol 27: 297–302.
177. Zhukov OD (1999). (1999). [Distribution of N-([1-14C]-palmitoyl)ethanolamine in rat tissues]. Ukr Biokhim Zh 71: 124–125.
178. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sørgård M, Di Marzo V et al. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452–457.
179. Zygmunt PM, Ermund A, Movahed P, Andersson DA, Simonsen C, Jönsson BA et al. (2013). Monoacylglycerols activate TRPV1--a link between phospholipase C and TRPV1. PLoS One 8.e81618